Intriguing Insights of Pharma Drug Launches and Effective Strategies

With the advent of advanced technologies, the pharma industry is undergoing a shift in its operational strategies, especially when it comes to new drug launches. Moreover, with the increased competition in the market, pharma companies need to embrace a data-driven approach to evaluate their drug pipelines to better comprehend the factors that drive effective commercial and planning execution. This is the need of the hour as launches are becoming more frequent, confined, and challenging. A recent McKinsey report has also predicted that there would be a steep rise in new products as compared to last year. And given this external landscape, flooded with more products of wide diversity, it’s never more crucial for pharma enterprises to rack the new product launch code.

In contrast, there isn’t a lucid definition of drug launch success. Drugs can be delisted from formularies, which would be equivalent to a consumer goods product being omitted from the store’s inventory; but in reality, it’s more likely for a new drug to not get on formularies in the first place rather than be delisted from them. In most cases, the success of a drug launch is calculated by delivery against Enterprise/Wall Street expectations or by comparing the market share of advanced drugs vs. competitors at the same level. Based on the measure of success, researchers have shown that a significant percentage of new drugs fall short of target forecasts, indicating that drug launch success is also not great.

This article will delve into the reasons why most drug launches fail and the best strategies that pharma companies can adopt to implement a successful launch.

Reassessing the Traditional Drug Launch Planning Methodology: Why it Fails to Meet Expectations

There are numerous reasons why the launch of an advanced drug might fail to meet its external or internal analyst expectations:

• Launch readiness: Generally, launch teams have 3 to 5 years to prepare for a drug launch, which gives them plenty of time to get ready. However, teams have to be that much prompt in gearing up for an accelerated launch because of an unexpected breakthrough designation status by the FDA. Several pharma enterprises are also killing time until the last minute to make launch decisions based on phase three clinical data, which can lead to launch teams scrambling to have materials ready by the approval date. Some drugs even launch with just the PI and don’t even have a core visual aid (CVA) ready.
  
  
• Inaccurate forecasting: Though the drug launch forecast is in place, pharma companies don’t always put it into consideration, rendering the whole effort (time and money)- null. This makes the pharma market research still a challenge, even today. It is estimated that at least one in three forecasts are not accurate, and the real-world results of a drug launch don’t impact the way it is expected. The launch prediction methodology in the pharma industry may need a revamp, and significantly different market research as well as modelling techniques might be necessary to enhance the accuracy of launch forecasts. As of late, scientists have discovered that forecasting inaccuracies differ significantly based on the classification of the pharma enterprise that is initiating the product launch. As of late, big shot pharma products are levied significantly while petty drugs are unvaryingly overestimated. 
  
  
• Suppositions at Launch: Several suppositions take form during a drug launch plan approach, and while marketing teams conduct vehement market research and data analytics to validate their assumptions, it is possible for the market to shift by the time the advanced drug is introduced in ways that were not foreseen by the team.

Within these circumstances, launch teams end up placing the incorrect strategic bets and not accounting for unexpected competitive or market events during the strategic planning process. Inaccuracies in launch strategy can manifest themselves in the form of brand value propositions that don’t connect with customers, brand positionings that are not differentiated, price points, reimbursement strategies that form major barriers to market access, and more.

• Gap between execution and strategy: While countable launch teams get their strategy inaccurate, it is more common for launch teams to not execute well on their strategies. Since launch planning is extended over a multi-year process, it is seamless for launch teams to make incremental decisions over time and gradually end up with launch executions that are not derived from their launch strategic thinking.

Here are some of the proven factors on which pharma companies should focus to enhance their product launch strategies-

• Effective Differentiation through Messaging: Differentiation is vital in today’s competitive pharma market for companies. A Bain study found that companies with the most effective messaging follow 3 fundamental guidelines:
• Interpret research into actionable insights- where companies utilize market research tools (like patient pathways, HCP segmentation, etc) and only those with successful launches interpret market data into actionable insights to make their product unique.
• Practice post-launch studies- to ensure data quality and fill in data gaps.
• Address, discover, and message to HCP and patient pain points, which aligns the company’s new launches and offers additional support to address the consumer’s challenges.

Companies like Newristics are revolutionizing heuristic-based messaging strategies, which are driving conversion of HCPs, adherence of patients, and effective knowledge sharing.

• Forging Trust Through Advocacy and Experience: When it comes to prescribing a drug by a clinician, they have choices, and a new drug won’t seem promising unless they understand its benefits and how it improves patient care.

Awareness and building trust with primary stakeholders are important for companies to build a robust brand recognition and reputation. Medical affairs foster advocacy by building relationships with KOLs, engaging in scientific exchanges, and addressing clinical concerns through peer-reviewed evidence. Subsequently, commercialization teams boost the prescriber and patient experience by ensuring seamless access and operational support.

• Fostering a Team and Strategizing Plans: To specialize in launch excellence, successful enterprises form a strategic in-house team. This approach gives launch teams the authority and agility to make decisions that are best for the brand or the patient. Forming dedicated launch task forces with transparent roles, streamlined communication, and a prompt decision-making framework allows for the agility needed to adapt quickly to challenges.
  
  
• Looping Feedbacks: Establishing strong feedback loops is vital for refining strategies and adapting to market dynamics. Post-launch monitoring is important in the first few months after the product enters the market and initiates its journey to patent expiration. At this point, the field force can be a crucial factor in providing feedback based on conversations with KOLs, HCPs, and other stakeholders. By centralizing the insights gained from the conversations into one integrated platform, teams can identify patterns, address stakeholder concerns, and perpetually enhance their strategies to meet market needs.
  
  
• Effectively Sharing Market Research: Gone are the days when life science companies can no longer rely solely on clinical trial data, expecting prescribers and payers will recognize the value of a drug or device. Communicating Health Economics and Outcomes Research (HEOR) constructively is now important for securing market access and shaping prescribing behaviours. By exhibiting a comprehensive view of the disease landscape and patient population, teams can build a stronger case to enhance market access, optimize formulary positioning, and influence prescribing habits. Capitalizing on an insights management platform (IMP) streamlines market research, allowing teams to engage multiple audiences more efficiently, at a cheaper rate, and within minimal timeframes.
  
  

The key benefits of an IMP include accelerating market intelligence, understanding strategic impact, and enabling teams to optimize siloed data while organizing historical insights and gaining deeper intelligence on competitors. These, in turn, leverage various stages of product development, starting from planning successful launches to forming effective marketing strategies. 

Conclusion

Attaining launch excellence requires simultaneous efforts from medical affairs and commercialization teams. While compliance and regulatory needs necessitate separation, these teams can optimize how they control certain elements and align their strategies and shared tools. By strategic implementations of advanced technologies to analyse data and produce actionable insights, coordinated leadership, agile workflows, and pharma enterprises entering product launches can overcome resource constraints, differentiate their products, and build trust with stakeholders.